Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,674 other S bills in the 119th — cohort avg 32d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (15)
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2026 · third_quarter · Health Issues
Lobbying Issues Description: Budget and appropriations for public health, disease and injury prevention, including obesity and related diseases; pandemics and emerging infectious diseases; physical activity; public health preparedness; nutrition programs; environmental health; health equity; community-based public health interventions; public health infrastructure and workforce; maternal health; substance misuse/behavioral health issues; vaccines and immunizations; antimicrobial resistance; public health data modernization; global health. Specific Legislation: 1.Preventing Adverse Childhood Experiences Act (Not yet introduced) 2.Mental Health Services for Students Act (H.R.5557) 3.Helping Kids Cope Act (Not yet introduced) 4.Advancing Student Services in Schools Today Act (S.2050) 5.Pursuing Equity in Mental Health Act (H.R.2904/S.1448) 6.RISE from Trauma Act (S.3461/H.R.6625) 7.Better Mental Health Care for Americans Act (Not yet introduced) 8.Reentry Act (H.R. 2586) 9.FY 2027 Labor, HHS, Education and Related Agencies Appropriations 10.FY 2027 Agriculture, Rural Development and Drug Administration Appropriations, provisions related to nutrition 11.Farm, Food, and National Security Act of 2026 12.Improving Social Determinants of Health Act (Not yet introduced) 13.The UNDERSTAND Act (Not yet introduced) 14.The TRUTH in Labeling Act (Not yet introduced) 15.Child Nutrition Reauthorization 16.Promoting Physical Activity for Americans Act (H.R. 6121) 17.Momnibus Act (H.R.7973) 18.Older Americans Act Reauthorization (S.2120) 19.Protecting the Health of Americas Older Adults Act (Not yet introduced) 20.Pandemic and All-Hazards Preparedness Act Reauthorization (Not yet introduced) 21.Public Health Infrastructure Saves Lives Act (Not yet introduced) 22.The Support for Patients and Communities Reauthorization Act (H.R. 2483/S.2121) 23.The PEER Support Act (H.R.2741/S.1329) 24.The Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S.931/ H.R.2509) 25.The 9-8-8 Implementation Act (H.R10280) 26.Local 988 Response Act (Not yet introduced) 27.Lead-Safe Housing for Kids Act (S. 5455) 28.The Kid PROOF Act (H.R.6396) 29.EARLY Minds Act (S.779/H.R.1735) 30.Campus Prevention and Recovery Services for Students Act (H.R.7019) 31.Stabilization to Prevent (STOP) Suicide Act (H.R.8124) 32.Womens Heart Health Expansion Act of 2026 (S.3944) 33.Childhood Diabetes Reduction Act (Not yet introduced) 34.Raising Awareness for Youth Suicide Prevention (RAYS) Act (H.R.7092/S.4061) 35.Campus Lifeline Act of 2026 (H.R.8657) 36.Improving Mental Health Access for Students Act (S.1924/H.R.3624) 37.9-8-8 CONNECT Act (H.R.8122) 38.Improving Non-medical Drivers of Health Act (Not yet introduced) 39.Alzheimers Screening and Prevention Act (H.R.6130) 40.Tech to Save Moms Act (S. 958/H.R. 8317) 41.BUILD America 250 Act (H.R.8870)/Surface transportation reauthorization 42.Extreme Heat Congressional Advisory Commission Act(H.R.9301) 43.Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act (HR 7252/S. 4875) 44.FY 2028 Labor, HHS, Education, and Related Agencies Appropriations 45.Barriers to Suicide Act (S.5558/H.R.3505) House(s) of Congress and Federal Agencies lobbied during the quarter: House, Senate, White House Domestic Policy Council, HHS, CDC, FDA, USDA, OMB, HRSA, SAMHSA, and Federal Communications Commission (FCC).
Client expense: $45,651 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), White House Office
2026 · third_quarter · Health Issues
Legislation and policies relating to: Potential changes in authorizations for nurse education, workforce, and research programs as a result of workforce reductions and reorganization of agencies and programs within the Department of Health and Human Services Policies related to the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices, child vaccine recommendations and schedule, the Vaccines For Children Program, and the Vaccine Injury Compensation Fund Executive Order, Delivering Gold Standard Childhood Vaccine Recommendations For Americans, and the Department of Health and Human Services request for information, Categories Used in Federal Vaccine Recommendations and the Role of Shared Clinical Decision-Making (Docket No. HHS-OS-2026-0332) Cancellation of federal nursing workforce grants Adoption of recommendations of the National Academy of Medicine report, The Future of Nursing 2020-2030: Charting a Path to Achieve Health Equity Provisions of the Patient Protection & Affordable Care Act (P.L. 111-148) Use of provider-neutral and inclusive language in federal documents, forms, surveys, and legislation, including draft legislation, the Doctors Not AI Act Reauthorization of the Child Nutrition Act Implementation of 42 USC 300gg-5(a) regarding provider non-discrimination by health plans Policies affecting nurse practitioner education and workforce, including pediatric health care workforce shortages Definition, evaluation and enforcement of essential health benefits and provider network adequacy Mental health services and violence prevention, including draft legislation, the Public Safety Mental Health Fellowship Act Childrens online safety and protection of minors using artificial intelligence chatbots Tobacco and vaping prevention and cessation Implementation of provisions of the One Big, Beautiful Bill Act (PL 119-21) H.R. 1435/S. 3714, Family-to-Family Reauthorization Act of 2025 H.R. 1735/S. 779, Early Action and Responsiveness Lifts Youth Minds (EARLY Minds) Act H.R. 2493, Improving Care in Rural America Reauthorization Act of 2025 H.R. 3333, Magnifying Opportunities to Recruit and Educate (MORE) Nurses Act H.R. 3624/S. 1924, Improving Mental Health Access for Students Act H.R. 3701, Family Vaccine Protection Act H.R. 3884/S. 2011, Telemental Health Care Access Act H.R. 4262/S. 4110, Educating Medical Professionals and Optimizing Workforce Efficiency and Readiness (EMPOWER) for Health Act H.R. 4340/S. 921, Tyler's Law H.R. 4564, Dillons Law H.R. 4709, Newborn Screening Saves Lives Reauthorization Act of 2025 H.R. 4725, Transparency, Readability, Understandability, Truth, and Helpfulness (TRUTH) in Labeling Act H.R. 5145, Bipartisan Premium Tax Credit Extension Act H.R. 5434/S. 2826, 988 LGBTQ+ Youth Access Act of 2025 H.R. 5469/S. 2858, Stillbirth Health Improvement and Education (SHINE) for Autumn Act H.R. 5582/S. 2355, Patients Deserve Price Tags Act H.R. 6088/S. 3281, Restoring Food Security for Families & Farmers Act of 2025 H.R. 6121/S. 2303, Promoting Physical Activity for Americans Act H.R. 6252, Food Assurance and Security Act H.R. 6396, Kid Providing Resources for Optimal Outcomes against Fatalities (Kid PROOF) Act of 2025 H.R. 6561, PREVENT HPV Cancers Act of 2025 H.R. 6703, Lower Health Care Premiums for All Americans Act H.R. 6844, Tobacco TRACE Act H.R. 6845/S. 3569, S.T.O.P. Illegal Vaping Act H.R. 6945/S. 4242, Supporting Pregnant and Parenting Women and Families Act H.R. 7092/S. 4061, Raising Awareness for Youth Suicide (RAYS) Prevention Act H.R. 7352/S. 4875, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act H.R. 7567, Farm, Food, and National Security Act of 2026 H.R. 7757, Kids Internet and Digital Safety (KIDS) Act H.R. 7867, Infant Formula Safety Modernization Act of 2026 H.R. 7875, Providing Opportunities for Individuals in Need of Treatment and Support (POINTS) Act H.R. 7973/S. 5283, Momnibus Act H.R. 8081/S. 4202, Mental Health Access and Provider Support Act H.R. 8089/S. 4186, Perinatal Workforce Act H.R. 8163/S. 5180, Provider Reimbursement Stability Act H.R. 8201, Expanding Community Access to Health Services Act H.R. 8209, School-Based Health Centers Reauthorization Act of 2026 H.R. 8385, Food Labeling Modernization Act of 2026 H.R. 8425, Strengthening the Vaccines for Children Program Act of 2026 H.R. 8429, Baby Food Safety Act of 2026 H.R. 8521/S. 4387, Protect Moms from Domestic Violence Act H.R. 8657/S. 5305, Campus Lifeline Act H.R. 9257/S. 4754, Primary and Behavioral Health Care Access Act H.R. 9393, Lower Costs, More Transparency Act of 2026 H.R. 10280, 9-8-8 Implementation Act of 2026 S. 272, Protect Infant Formula from Contamination Act S. 278, Kids Off Social Media Act S. 705, Innovations in Pediatric Drugs Act S. 836/H.R. 6291, Children and Teens Online Privacy Protection Act (COPPA 2.0) S. 891, Bipartisan Health Care Act S. 1157/H.R. 2319, Women and Lung Cancer Research and Preventive Services Act of 2025 S. 1482/H.R. 4407, National Nursing Workforce Center Act of 2025 S. 1599/H.R. 6394, Midwives for Maximizing Optimal Maternity Services (MOMS) Act of 2025 S. 1748/H.R. 6484, Kids Online Safety Act S. 1874/H.R. 3593, Title VIII Nursing Workforce Reauthorization Act of 2025 S. 2169, Rural Hospital Cybersecurity Enhancement Act S. 2857/H.R. 5448, Protecting Free Vaccines Act S. 2954, Health Care Workforce Expansion Act of 2025 S. 3062/H.R. 8623, Guidelines for User Age-verification and Responsible Dialogue (GUARD) Act of 2025 S. 3199, 988 Lifeline Location Improvement Act of 2025 S. 3315, Health Care Cybersecurity and Resiliency Act of 2025 S. 3386, Health Care Freedom for Patients Act of 2025 S. 3402, Ensuring Excellence in Mental Health Act S. 3799, Healthy Start Reauthorization Act of 2026 S. 3853, End the Vaccine Carveout Act S. 4088, Welcome Back to the Health Care Workforce Act S. 4141, Rural Hospital Revitalization Act S. 4189, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act S. 5090, Digital Age Assurance Act of 2026
2026 · third_quarter · Health Issues
FY 2026 Appropriations for Agencies ---Administration for Strategic Preparedness and Response (ASPR) ---Centers for Disease Control and Prevention (CDC) ---Centers for Medicare and Medicaid (CMS) ---Food & Drug Administration (FDA) ---Health Resources and Services Administration (HRSA) ---National Institutes of Health (NIH) FY 2026 Appropriations for Specific Issues ---Alternative Funding Programs ---Antimicrobial Resistance (General) ---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---CICP ---CMMI: GLOBE and GUARD Models ---Drug Pricing ---Funding for Strategic National Stockpile ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Influenza Planning & Response ---MCM PRV Reauthorization ---Pandemic Preparedness -R&D Funding for Medical Countermeasures ---Pediatric Priority Review Voucher ---Prescription Drug User Fee Act (PDUFA) VIII Implementation ---Project Bioshield ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Section 317 Immunization Program ---Vaccines and Infectious Diseases ---Vaccine Injury Compensation Program 340B Drug Discount Program ---H.R.5256: 340B ACCESS Act ---H.R.9504: Tax Exempt Hospital Transparency Act ---H.R.9599: SECURE 340B Act ---S.5244: SUSTAIN 340B Act ---Program Implementation & Oversight ---Rebate Models Accelerated Approval Artificial Intelligence (AI) Alternative Funding Programs Biodefense Research, Development and Procurement Issues (Non-Funding) ---Gain of function (Viral Gain of Function Research Moratorium Act, SAFE Risky Research Act) ---Implementation of BIOSECURE Act ---MCM PRV Program Reauthorization ---National Defense Authorization Act 2027 ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Risky Research Review Act ---VICP Loopholes Biosimilars ---H.R.10628/S.5571: Biosimilars Access and Affordability Act ---S.1414: Expedited Access to Biosimilars Act ---S.1954: Biosimilar Red Tape Elimination Act ---Biosimilars Competition (General) ---Interchangeability and Pharmacy Substitution Cell & Gene Therapy ---H.R.1672: Maintaining Investments in New Innovation (MINI) Act Clinical Trial Data in China ---Next-Generation U.S. Clinical Development to Accelerate Cures - Legislative Discussion Draft Data Privacy ---H.R.8413: SECURE Data Act ---Clinical Trial Data in China ---Implementation of BIOSECURE Act Diagnostics and Personalized Medicine Regulation and Oversight Diversity & Inclusion ---H.R.3521: Clinical Trial Modernization Act ---Decentralized Clinical Trials Drug Evaluation and Review ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---FDA Hiring Flexibility Drug Importation Drug Manufacturing, Quality & Distribution ---S.3788: CLEAR Labels Act ---Advanced Manufacturing ---Compounding Pharmacies ---Drug Shortages ---Supply Chain Integrity and Traceability Drug Patenting ---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act ---S.2658: Medication Affordability and Patient Integrity Act Drug Pricing ---H.R.1492/S.832: Ensuring Pathways to Innovative Cures (EPIC) Act ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.5391/S.2764 Protecting Patient Access to Cancer and Complex Therapies Act ---H.R.9418: Access to Innovative Treatments Act of 2026 ---S.526: Pharmacy Benefit Manager Transparency Act ---S.1097: Interagency Patent Coordination and Improvement Act ---S.1954: Biosimilar Red Tape Elimination Act ---S.3014: Ensuring Timely Access to Generics ---CMMI Authority ---Ensuring Access to Generic Medications Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Implementation of ORPHAN Cures Act ---International Pricing Policies ---Tariffs Efforts to Expand the Bioeconomy & Biomanufacturing ---H.R.8930: Federal Biotechnology Workforce Assessment Act ---H.R.8938: Biotechnology Workforce Alignment Act of 2026 Foreign Drug Data Protection Law ---Implementation of BIOSECURE Act Generic Drug Entry ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.1095: Stop STALLING Act ---Generic Drug Application Review Reforms ---Incentives for Generic Entry Issues Relating to Medical Research and Animal Testing ---FDA Modernization Act 3.0 Medicaid ---S.526: Pharmacy Benefit Manager Transparency Act ---Alternative Payment Arrangements for Gene Therapies ---Drug Benefit Design ---Most Favored Nation Drug Pricing Proposals ---Pricing and Rebates National Defense ---Medical Countermeasure Priority Review Voucher Reauthorization ---H.R.8800: National Defense Authorization Act for Fiscal Year 2027 National Security ---H.R.10568: Protecting Biological Data as Critical Infrastructure Act ---H.R.10569: Protecting Biotechnology and Biomanufacturing as Critical Infrastructure Act ---S.3741: Biosecurity Modernization and Innovation Act of 2026 ---Clinical Trial Data in China ---CMMI: GLOBE and GUARD Models ---Implementation of BIOSECURE Act ---International Pricing Policies ---Medical Countermeasure Priority Review Voucher Reauthorization ---NSC/OSTP priorities ---Nucleic acid synthesis security and biotechnology governance Opioid Crisis ---Non-Opioid Analgesics Orphan Drug Issues ---H.R.1414: Cameron's Law ---Implementation of ORPHAN Cures Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Orphan Drug Tax Credit Pandemic Preparedness ---Drug Supply Chain Management ---R&D Funding for Medical Countermeasures ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Supply Chain Issues Precision Medicine Initiative Rare Pediatric Disease Priority Review ---H.R.10359: Priority for Pediatric Cures Act ---S.822: Scientific EXPERT Act ---Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products ---H.R.5509/S.2903:SAFE STEP Act ---S.864/H.R.6423: HELP Copays Act ---Access to Innovative Treatments ---CMMI Authority ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Medicare Part B Physician-Administered Products ---National Coverage Determination ---Patient Cost-Sharing and Smoothing ---Prior Authorization Reform ---Protected Classes ---Step Therapy ---Support of Patient Premiums and Cost-Sharing Obligations ---Value-Based Contracting and Communications ---Value-Based Purchasing (VBP) Rule Vaccines and Infectious Diseases ---H.R.5509/S.2903: SAFE STEP Act ---H.R.7352/S.4875: PASTEUR Act of 2026 ---H.R.9418: Access to Innovative Treatments Act of 2026 ---H.R.9672: Vaccine Injury Compensation Modernization Act of 2026 ---Adult Immunization ---Maternal Immunization ---MCM Manufacturing & Capacity ---MCM R&D Incentives ---Monoclonal Antibody Coverage and Utilization ---Senate Discussion Draft - Vaccine Injury Protection Act ---Vaccine and Antimicrobial Resistance Product Development and Incentives ---Vaccine Injury Compensation Program ---Vaccine Safety ---Vaccine Safety Net and Vaccine Infrastructure ---Value of Vaccines and Vaccine Confidence
2026 · third_quarter · Medical/Disease Research/Clinical Labs
FY 2026 Appropriations for Agencies ---Administration for Strategic Preparedness and Response (ASPR) ---Biomedical Advanced Research and Development Authority (BARDA) ---Centers for Disease Control and Prevention (CDC) ---Food & Drug Administration (FDA) ---Health Resources and Services Administration (HRSA) ---National Institutes of Health (NIH) FY 2026 Appropriations for Specific Issues ---Antimicrobial Resistance (General) ---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---Funding for Medical Countermeasures ---Funding for Section 317 ---Funding for Strategic National Stockpile ---Pandemic Preparedness - R&D Funding for Medical Countermeasures ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---VICP/CICP Antimicrobial Resistance ---H.R.7352/S.4875: PASTEUR Act of 2026 Biodefense Research, Development and Procurement Issues ---Medical Countermeasure Priority Review Voucher Reauthorization CDC Reform Pandemic Preparedness ---Medical Countermeasure Priority Review Voucher Reauthorization ---R&D Funding for Medical Countermeasures
Client expense: $2,560,000 · Firm income: Not reported
2026 · third_quarter · Medical/Disease Research/Clinical Labs
H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS S. 1406: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS S. 4875: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS (DRAFT) CLINICAL TRIAL MODERNIZATION ACT; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSION ON FY2027 APPROPRIATIONS; PROVISIONS RELATED TO DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) AND RELATED AGENCIES, FOOD AND DRUG ADMINISTRATION (FDA) AND RELATED AGENCIES, CENTERS FOR DISEASE CONTROL AND PREVENTION AND RELATED AGENCIES, NATIONAL INSTITUTES OF HEALTH (NIH) AND RELATED AGENCIES, OBLIGATE STABLE PACE OF SPENDING FY26 FUNDS GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NATIONAL INSTITUTES OF HEALTH (NIH) RESEARCH GRANTS; PROVISIONS RELATED TO PRESERVING THE LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSION OPPOSING OFFICE OF MANAGEMENT AND BUDGET'S (OMB) PROPOSED RULE, REGULATION FOR FEDERAL FINANCIAL ASSISTANCE (RELEASED 5/29/26) CFF SUBMITS COMMENTS TO ORGAN PROCUREMENT & TRANSPLANT NETWORK (OPTN)/HEALTH RESOURCES & SERVICES ADMINISTRATION (HRSA) IN RESPONSE TO OPTN'S UPDATE ON LUNG CONTINUOUS DISTRIBUTION POLICY PROPOSAL CFF SUBMITS COMMENTS IN RESPONSE TO A REQUEST FOR INFORMATION (RFI) FROM THE FOOD AND DRUG ADMINISTRATION (FDA) ON EXPEDITED INVESTIGATIONAL NEW DRUG PILOT PROGRAM CFF SUBMITS COMMENTS TO DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) IN RESPONSE TO PROPOSED REGULATION ON CLINICAL TRIALS CFF SUBMITS COMMENT TO FOOD AND DRUG ADMINISTRATION (FDA) IN RESPONSE TO DRAFT GUIDANCE ON LEVERAGING PRIOR KNOWLEDGE IN THE DEVELOPMENT OF HUMAN GENE THERAPY PRODUCTS INCORPORATING GENOME EDITING
| Republican |
| IN |
Client expense: Not reported · Firm income: $24,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE
Client expense: $2,560,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $170,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
2026 · third_quarter · Health Issues
H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS S. 1406: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS S. 4875: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS ON NEW MEDICAID WORK REPORTING REQUIREMENTS AND DEFINITION OF MEDICAL FRAILTY DESCRIBED IN CMS-2454-IFC GENERAL DISCUSSIONS SURROUNDING NON-COMPREHENSIVE INSURANCE PRODUCTS, EXPANSION OF HIGH-DEDUCTIBLE HEALTH PLANS (HDHPs) PAIRED WITH HEALTH SAVINGS ACCOUNTS (HSAs) GENERAL DISCUSSION ON ALTERNATIVE FUNDING PROGRAMS (AFPS) GENERAL DISCUSSION ON DRUG PRICING REFORM GENERAL DISCUSSION ON HEALTH COVERAGE REFORM GENERAL DISCUSSIONS ON PHARMACY BENEFIT MANAGERS (PBMs) REFORM INCLUDING TRANSPARENCY AND ACCOUNTABILITY, SPREAD PRICING AND PRICE-LINKED COMPENSATION GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NATIONAL INSTITUTES OF HEALTH (NIH) RESEARCH GRANTS; PROVISIONS RELATED TO PRESERVING THE LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL RECONCILIATION LEGISLATION CFF SUBMITS COMMENTS TO CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) IN RESPONSE TO THEIR REQUEST FOR INFORMATION ON THE AFFORDABLE CARE ACT'S (ACA) ESSENTIAL HEALTH BENEFITS CFF SUBMITS COMMENTS IN RESPONSE TO DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) AND CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) REQUEST FOR INFORMATION ON HOW TO IMPLEMENT PBM MEASURES INCLUDED IN THE LAST CONSOLIDATED APPROPRIATIONS ACT CFF SUBMITS COMMENTS IN RESPONSE TO CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) INTERIM FINAL RULE ON THE MEDICAID WORK REPORTING REQUIREMENTS
Client expense: $170,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Lobbying Issues Description: Budget and appropriations for public health, disease and injury prevention, including obesity and related diseases; pandemics and emerging infectious diseases; physical activity; public health preparedness; nutrition programs; environmental health; health equity; community-based public health interventions; public health infrastructure and workforce; maternal health; substance misuse/behavioral health issues; vaccines and immunizations; antimicrobial resistance; public health data modernization; global health. Specific Legislation: 1.Preventing Adverse Childhood Experiences Act (Not yet introduced) 2.Mental Health Services for Students Act (H.R.5557) 3.Helping Kids Cope Act (Not yet introduced) 4.Advancing Student Services in Schools Today Act (S.2050) 5.Pursuing Equity in Mental Health Act (H.R.2904/S.1448) 6.RISE from Trauma Act (S.3461/H.R.6625) 7.Better Mental Health Care for Americans Act (Not yet introduced) 8.Reentry Act (H.R. 2586) 9.FY 2027 Labor, HHS, Education and Related Agencies Appropriations 10.FY 2027 Agriculture, Rural Development and Drug Administration Appropriations, provisions related to nutrition 11.Farm, Food, and National Security Act of 2026 12.Improving Social Determinants of Health Act (Not yet introduced) 13.The UNDERSTAND Act (Not yet introduced) 14.The TRUTH in Labeling Act (Not yet introduced) 15.Child Nutrition Reauthorization 16.Promoting Physical Activity for Americans Act (H.R. 6121) 17.Momnibus Act (H.R.7973) 18.Older Americans Act Reauthorization (S.2120) 19.Protecting the Health of Americas Older Adults Act (Not yet introduced) 20.Pandemic and All-Hazards Preparedness Act Reauthorization (Not yet introduced) 21.Public Health Infrastructure Saves Lives Act (Not yet introduced) 22.The Support for Patients and Communities Reauthorization Act (H.R. 2483/S.2121) 23.The PEER Support Act (H.R.2741/S.1329) 24.The Connecting Our Medical Providers with Links to Expand Tailored and Effective (COMPLETE) Care Act (S.931/ H.R.2509) 25.The 9-8-8 Implementation Act (H.R10280) 26.Local 988 Response Act (Not yet introduced) 27.Lead-Safe Housing for Kids Act (S. 5455) 28.The Kid PROOF Act (H.R.6396) 29.EARLY Minds Act (S.779/H.R.1735) 30.Campus Prevention and Recovery Services for Students Act (H.R.7019) 31.Stabilization to Prevent (STOP) Suicide Act (H.R.8124) 32.Womens Heart Health Expansion Act of 2026 (S.3944) 33.Childhood Diabetes Reduction Act (Not yet introduced) 34.Raising Awareness for Youth Suicide Prevention (RAYS) Act (H.R.7092/S.4061) 35.Campus Lifeline Act of 2026 (H.R.8657) 36.Improving Mental Health Access for Students Act (S.1924/H.R.3624) 37.9-8-8 CONNECT Act (H.R.8122) 38.Improving Non-medical Drivers of Health Act (Not yet introduced) 39.Alzheimers Screening and Prevention Act (H.R.6130) 40.Tech to Save Moms Act (S. 958/H.R. 8317) 41.BUILD America 250 Act (H.R.8870)/Surface transportation reauthorization 42.Extreme Heat Congressional Advisory Commission Act(H.R.9301) 43.Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act (HR 7252/S. 4875) 44.FY 2028 Labor, HHS, Education, and Related Agencies Appropriations 45.Barriers to Suicide Act (S.5558/H.R.3505) House(s) of Congress and Federal Agencies lobbied during the quarter: House, Senate, White House Domestic Policy Council, HHS, CDC, FDA, USDA, OMB, HRSA, SAMHSA, and Federal Communications Commission (FCC).
Client expense: $41,651 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Education, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), White House Office
2026 · third_quarter · Health Issues
Issues related to diagnostic testing, Oncology, Hepatitis C funding H.R.7352/S.4875, the Pioneering Antimicrobial Subscriptions To End Upsurging Resistence Act of 2026 (PASTEUR Act) S.1941, the Cure Hepatitis C Act of 2025
Client expense: $310,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Health Issues
Antimicrobial resistance; advanced molecular detection; national wastewater surveillance system (S.4048 - PREDICT Act); PAMA reform: RESULTS Act (H.R. 5269 S.2761); PASTEUR Act (H.R. 7352 and S. 4875); SUPER BUGS Act (H.R. 7879), and Stop Superbugs Act (S.5237).
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
H.R. 1, One Big Beautiful Bill Act, implementation and patient access issues. S. 1816/H.R. 3514, Improving Seniors' Timely Access to Care Act. S. 1717/H.R. 5343, Ensuring Patient Access to Critical Breakthrough Products Act. H.R. 3521/S. 4440, Clinical Trial Modernization Act. S. 2903/H.R. 5509, Safe Step Act. FY 2027 Labor, HHS, Education appropriations for programs affecting people with chronic diseases and disabilities. S. 494/ H.R.1189 National Plan for Epilepsy Act Senate Finance Committee RFI on Drug Pricing and Health Coverage H.R. 9599 SECURE 340B Act Discussion Draft - 340B Drug Pricing Integrity and Affordability for Patients Act S. 5244 SUSTAIN 340B Act H.R.7352/S. 4875 PASTEUR Act S.3267/H.R. 6130 ASAP Act
Client expense: $21,227 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
S. 380/H.R. 1254 - Rural Obstetrics Readiness Act S. 4875/H.R. 7352 - PASTEUR Act of 2026 Reauthorization of the Pandemic and All-Hazards Preparedness Act Tobacco Control Public Health Infrastructure Healthy People 2030 Objectives Chronic Disease of Addiction Federal Vaccine Recommendations Physician Fee Schedule
Client expense: $45,745 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Medical/Disease Research/Clinical Labs
Legislation related to anti-microbial resistance generally Infectious diseases physician work force issues generally H.R.7352 and S. 4875 (PASTEUR Act of 2026), entire bill
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2026 · third_quarter · Medicare/Medicaid
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Issues related to point of care testing and digital pathology; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to infectious disease diagnostics.
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Health Issues
S. 5237, Stop Superbugs Act, Issues pertaining to NIAID grantmaking for antibiotic-resistant infection research. H.R. 7352, S. 4875, PASTEUR Act, Issues pertaining to antimicrobial drug development. H.R. 766, SEWER Act, Issues pertaining to CDC wastewater surveillance activities. S. 4048, PREDICT Act, Issues pertaining to CDC wastewater surveillance activities.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medical/Disease Research/Clinical Labs
Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (H.R.7352/S.4875 119th Congress),Administration Executive Orders regarding HHS, NIH, HRSA, FDA, and CDC, Public Health and Bio-Preparedness Workforce Loan Repayment Reauthorization Act (119th Congress, H.R. 4445/S.4283), SUPERBUGS Act, H.R.7879, 119th Congress.
Client expense: $290,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2026 · second_quarter · Health Issues
Infectious diseases (generally, no specific legislation); antimicrobial (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza (generally, no specific legislation); public health security and bio-defense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); President's Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White Care Act (generally, no specific legislation); P, Infectious diseases and bio-preparedness health professionals loan repayment issues, ID incentive payments (no specific information or bill numbers), CMS Medicare Physician Fee Schedule, avian flu outbreak (generally, no specific bill), Administration executive orders regarding HHS, NIH, CDC, HRSA, FDA, and USAID FY2026, H.R. 4445/S.4283 Bio-Preparedness Workforce Pilot Program/Public Health Loan Repayment reauthorization legislation, J-1 Visa and Conrad 30 issues, H-1B Visa issues, 2026 CMS practice expense final rule, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act (PASTEUR)(H.R. 7352/S.4875, upcoming legislation on CMS practice expense cuts, 2027 CMS Medicare Physician Fee Schedule proposed rule, H.R. 9693, Patients First Act
Client expense: $290,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
2026 · second_quarter · Medical/Disease Research/Clinical Labs
H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS H.R. 7879: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2026; ALL PROVISIONS S. 1406: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS S. 4875: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; ISSUES RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSION ON FY2027 APPROPRIATIONS; ISSUES RELATED TO HHS AND RELATED AGENCIES, FDA AND RELATED AGENCIES, CDC AND RELATED AGENCIES, NIH AND RELATED AGENCIES, OBLIGATE STABLE PACE OF SPENDING FY26 FUNDS GENERAL DISCUSSION OPPOSING OMBS PROPOSED RULE, REGULATION FOR FEDERAL FINANCIAL ASSISTANCE, RELEASED 5/29 FOLLOW UP ON ALTERNATIVE FUNDING PROGRAMS AND IMPORTATION OF DRUGS; CFF SENDS LETTER TO FDA AND CDER REGARDING A CITIZEN PETITION CONCERNING ALTERNATIVE FUNDING PROGRAMS (AFPS) COMMENTS ON DRAFT GUIDANCE FOR THE PLAUSIBLE MECHANISM FRAMEWORK; CFF SUBMITS COMMENTS TO THE FDA ON DRAFT GUIDANCE FOR THE PLAUSIBLE MECHANISM FRAMEWORK, URGING A FLEXIBLE APPROACH TO SUPPORT THE DEVELOPMENT OF GENE EDITING AND OTHER THERAPIES FOR PEOPLE WITH ULTRA-RARE MUTATIONS
Client expense: $270,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS H.R. 4317: PHARMACY BENEFIT MANAGER (PBM) REFORM ACT OF 2025; ALL PROVISIONS H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS H.R. 6837: TO AMEND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974 TO ENSURE THAT PHARMACY BENEFIT MANAGERS ARE CONSIDERED FIDUCIARIES, AND FOR OTHER PURPOSES; ALL PROVISIONS H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS H.R. 7879: SAVING US FROM PANDEMIC ERA RESISTANCE BY BUILDING A UNIFIED GLOBAL STRATEGY (SUPER BUGS) ACT OF 2026; ALL PROVISIONS H.R. 7895: PBM KICKBACK PROHIBITION ACT; ALL PROVISIONS S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS S. 1406: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS S. 3549: PBM FIDUCIARY ACCOUNTABILITY, INTEGRITY, AND REFORM (FAIR) ACT S. 4875: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM GENERAL DISCUSSIONS ON NEW MEDICAID WORK REPORTING REQUIREMENTS AND DEFINITION OF MEDICAL FRAILTY DESCRIBED IN CMS IFR ON 6/1 GENERAL DISCUSSIONS SURROUNDING NON-COMPREHENSIVE INSURANCE PRODUCTS, EXPANSION OF HDHPS PAIRED WITH HSAS GENERAL DISCUSSION ON ALTERNATIVE FUNDING PROGRAMS (AFPS) GENERAL DISCUSSION ON DRUG PRICING REFORM GENERAL DISCUSSION ON HEALTH COVERAGE REFORM GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NIH RESEARCH GRANTS; ISSUES RELATED TO PRESERVING THE SENATES LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL BUDGET RECONCILIATION LEGISLATION CFF COMMENTS ON PRIOR AUTHORIZATION PROPOSED RULE; CFF SUBMITS COMMENTS FOR A PROPOSED RULE ON INTEROPERABILITY AND PRIOR AUTHORIZATION FOR DRUGS AND RELATED RFIS PPC STATEMENT IN RESPONSE TO CMS WORK REPORTING RULE; CFF JOINS PATIENT AND HEALTH GROUPS IN STATEMENT EXPRESSING CONCERN ABOUT THE CMS INTERIM FINAL RULE ON THE MEDICAID WORK CFF SENDS COMMENTS TO DOL ON PBM RULE; CFF SUBMITS COMMENTS TO DOL ON THEIR PROPOSED RULE TO IMPROVE TRANSPARENCY OF PHARMACY BENEFIT MANAGERS
Client expense: $270,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
2026 · second_quarter · Health Issues
Issues related to diagnostic testing, Oncology, Hepatitis C funding H.R.7352/S.4875, the Pioneering Antimicrobial Subscriptions To End Upsurging Resistence Act of 2026 (PASTEUR Act) S.1941, the Cure Hepatitis C Act of 2025
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · second_quarter · Health Issues
Issues related to point of care testing and digital pathology; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026.
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medicare/Medicaid
Issues related to reimbursement for diagnostic tests; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 7352/S. 4875 - PASTEUR Act of 2026; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act; Issues related to H.R. 6130/S. 3267 - ASAP Act.
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medical/Disease Research/Clinical Labs
Legislation related to anti-microbial resistance generally Infectious diseases physician work force issues generally H.R.7352 and S. 4875 (PASTEUR Act of 2026), entire bill
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Antimicrobial resistance; advanced molecular detection; national wastewater surveillance system (S.4048 - PREDICT Act); PAMA reform: RESULTS Act (H.R. 5269 S.2761); PASTEUR Act (H.R. 7352 and S. 4875); SUPER BUGS Act (H.R. 7879).
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Computer Industry
Kids online safety/privacy, HR 633 TAKE IT DOWN Act, HR 8187, Intimate Privacy Protection Act, Patent Reform, Artificial Intelligence, Content Moderation, Digital Replicas, Privacy, Section 230, Digital Trade Barriers, Privacy Working Group, space and spectrum policy, S 4875 No Fakes Act, Export Controls, DMA, S 278 Kids Off Social Media Act S. 2220 Prevail act, S 4533 Restore Act, S 2140 Patent Eligibility Restoration Act, S 281 TICKET Act, S 2114 Foreign Adversary Communications Transparency Act, HR 699 Email Privacy Act, Korea's Platform Regulation Bill, immigration reform, Australia Platform Regulation Bill, Artificial Intelligence, Protection Americans from Foreign Backdoor Act, Universal Service Fund, Congressional Review Act
Client expense: $130,000 · Firm income: Not reported
Government targets: Federal Communications Commission (FCC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. Trade Representative (USTR)
2025 · fourth_quarter · Computer Industry
Kids online safety/privacy, HR 633 TAKE IT DOWN Act, HR 8187, Intimate Privacy Protection Act, Patent Reform, Artificial Intelligence, Content Moderation, Digital Replicas, Privacy, Section 230, Digital Trade Barriers, Privacy Working Group, space and spectrum policy, S 4875 No Fakes Act, Export Controls, DMA, S 278 Kids Off Social Media Act S. 2220 Prevail act, S 4533 Restore Act, S 2140 Patent Eligibility Restoration Act, S 281 TICKET Act, S 2114 Foreign Adversary Communications Transparency Act, HR 699 Email Privacy Act, Korea's Platform Regulation Bill, immigration reform, Australia Platform Regulation Bill, Artificial Intelligence, Protection Americans from Foreign Backdoor Act, Universal Service Fund, Congressional Review Act
Client expense: $100,000 · Firm income: Not reported
Government targets: Federal Communications Commission (FCC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. Trade Representative (USTR)
2025 · third_quarter · Computer Industry
Kids online safety/privacy, HR 633 TAKE IT DOWN Act, HR 8187, Intimate Privacy Protection Act, Patent Reform, Artificial Intelligence, Content Moderation, Digital Replicas, Privacy, Section 230, Digital Trade Barriers, Privacy Working Group, space and spectrum policy, S 4875 No Fakes Act, Export Controls, DMA, S 278 Kids Off Social Media Act S. 2220 Prevail act, S 4533 Restore Act, S 2140 Patent Eligibility Restoration Act, S 281 TICKET Act, S 2114 Foreign Adversary Communications Transparency Act, HR 699 Email Privacy Act, Korea's Platform Regulation Bill, immigration reform, Australia Platform Regulation Bill, Artificial Intelligence, Protection Americans from Foreign Backdoor Act, Universal Service Fund, Congressional Review Act
Client expense: $70,000 · Firm income: Not reported
Government targets: Federal Communications Commission (FCC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. Trade Representative (USTR)
2025 · second_quarter · Computer Industry
S 5379 TRAIN Act, Kids online safety/privacy, HR 633 TAKE IT DOWN Act, HR 8187, Intimate Privacy Protection Act, Patent Reform, Artificial Intelligence, Content Moderation, Digital Replicas, Privacy, Section 230, Digital Trade Barriers, Tmobile/UScellular Transaction, Privacy Working Group, space and spectrum policy, S 4875 No Fakes Act, Export Controls, DMA, S 278 Kids Off Social Media Act S. 2220 Prevail act, S 4533 Restore Act, S 2140 Patent Eligibility Restoration Act, S 281 TICKET Act, S 2114 Foreign Adversary Communications Transparency Act, HR 699 Email Privacy Act, Korea's Platform Regulation Bill, immigration reform,
Client expense: $80,000 · Firm income: Not reported
Government targets: Federal Communications Commission (FCC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. Trade Representative (USTR)
2025 · second_quarter · Computer Industry
Licensing, competition, trade, and government procurement. Health IT procurement; health reform and related IT issues. Private sector preparedness; cyber research and development. Standards and interoperability. Competitiveness and high-tech sector. Policy issues in cloud computing. Open government, government IT modernization, open data, and technology choice. Supply chain security efforts within US government. Cybersecurity policies, legislation, protecting critical infrastructure, and International Cybersecurity norms. Legislative proposals related to government surveillance and data collection, including issues of transparency, FISA Section 702 reforms and ECPA reform. Non-disclosure order reform issues. Appropriations. Trade and trade agreements. Issues related to the EU US Privacy Shield agreement. Expanding access to K-12 computer science education. Issues related to the Privacy and Civil Liberty Review Board. Issues related to proposed changes to electronic communications transactional records (ECTRs). Issues related to Artificial Intelligence (AI), including Facial Recognition. Data breach legislation. Smart Spaces/Smart Infrastructure. Issues related to privacy; Federal privacy legislation. Issues related to children's privacy and safety. American Data Privacy and Protection Act (no bill number). Issues related to IT procurement, digital transformation, and modernization. Actions and guidance related to securing the information and communications technology and services supply chain. Open-Source Software Security. Unsubscribe Act (no bill number). National Community College Cybersecurity Challenge Act (no bill number). HR. 2385, CREATE AI Act. Authorization and Funding for the US AI Safety Institute. S. 146, TAKE IT DOWN Act. Issues related to non-consensual intimate imagery. SHIELD Act (no bill number). Issues related to Cloud Act and implementing agreements. Digital replicas. S. 4875, NO FAKES Act. S. 1894, H.R. 4059, SPEED Act. S. 5618, FoRGED Act.
Client expense: $2,570,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Science Foundation (NSF), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE, Securities & Exchange Commission (SEC), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Postal Service (USPS), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA)
2025 · second_quarter · Copyright/Patent/Trademark
1. General copyright law reform (including matters relating to songwriter royalty payments, licensing of musical works, the section 115 mechanical license, the Music Modernization Act, intellectual property enforcement, modernization/reform of the U.S. Copyright Office, and online streaming) 2. General algorithm legislation 3. DMCA Reform 4. Subscription related issues, including related to negative option rules 5. NO FAKES Act (S. 4875 / H.R. 9551) , NO AI FRAUD Act, PADRA, and general AI & digital replica related issues 6. Trade issues related to Canada, USMCA, and the Online Streaming Act
Client expense: $213,344 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Copyright Office
2025 · first_quarter · Copyright/Patent/Trademark
1. General copyright law reform (including matters relating to songwriter royalty payments, licensing of musical works, the section 115 mechanical license, the Music Modernization Act, intellectual property enforcement, modernization/reform of the U.S. Copyright Office, and online streaming) 2. General algorithm legislation 3. DMCA Reform 4. Subscription related issues, including related to negative option rules 5. NO FAKES Act (S. 4875 / H.R. 9551) , NO AI FRAUD Act, PADRA, and general AI & digital replica related issues 6. Trade issues related to Canada, USMCA, and the Online Streaming Act
Client expense: $141,190 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Copyright Office
2025 · first_quarter · Computer Industry
S 5379 TRAIN Act, Kids online safety/privacy, HR 633 TAKE IT DOWN Act, HR 8187, Intimate Privacy Protection Act, Patent Reform, Artificial Intelligence, Content Moderation, Digital Replicas, Privacy, Section 230, Digital Trade Barriers, Tmobile/UScellular Transaction, Privacy Working Group, space and spectrum policy, S 4875 No Fakes Act, Export Controls, DMA, S 278 Kids Off Social Media Act S. 2220 Prevail act, S 4533 Restore Act, S 2140 Patent Eligibility Restoration Act, S 281 TICKET Act, S 2114 Foreign Adversary Communications Transparency Act, HR 699 Email Privacy Act, Korea's Platform Regulation Bill, immigration reform,
Client expense: $80,000 · Firm income: Not reported
Government targets: Federal Communications Commission (FCC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Intl Trade Administration (ITA), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. Trade Representative (USTR)